News

The Pharma Letter4h
Gilead says Trodelvy ASCENT-03 study meets primary endpoint
US antivirals major Gilead Sciences (Nasdaq: GILD) yesterday released positive top-line results from the Phase III ASCENT-03 ...
The Pharma Letter23h
Reshaping HIV – how the journey from daily pills to long-acting therapies could take us closer to ending the HIV epidemic
Dr Kimberly Smith, Senior Vice President, Chief Scientific Officer, Head of Research & Development at ViiV Healthcare, ...